LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise. LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise.

X

Find the latest Drugs in Development and Pipeline Prospector News of The University of Texas MD Anderson Cancer Center.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
The University of Texas MD Anderson Cancer Center
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
1515 Holcombe Blvd. Houston, Texas 77030
Telephone
Telephone
1-855-900-4299
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.


Lead Product(s): Gemcitabine

Therapeutic Area: Oncology Product Name: RenovoGem

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: RenovoRx

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s clinical research expertise.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Recipient: Generate Biomedicines

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T-lymphocyte product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology.


Lead Product(s): Gamma Delta T-lymphocyte,Fludarabine Phosphate,Cyclophosphamide

Therapeutic Area: Oncology Product Name: OmnImmune

Highest Development Status: Phase IProduct Type: Cell and Gene therapy

Recipient: TC BioPharm

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna’s gene-edited induced pluripotent stem (iPS) cell therapeutic candidates to stimulate enhanced immune responses, including their effects on various aspects of T-cell mediated immunity.


Lead Product(s): iPSC-based Therapeutic

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

Recipient: Eterna Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

VG201 is a first-in-class oncolytic HSV-1 virus that has enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL15Rα.


Lead Product(s): VG201

Therapeutic Area: Oncology Product Name: VG201

Highest Development Status: Phase IProduct Type: Large molecule

Recipient: Virogin Biotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation, matching one of the ten TCRs within the Company’s TCR-T Cell Therapy.


Lead Product(s): TCR-T Cell Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Recipient: Alaunos Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Results from the trial will compare RTA 744 (berubicin) to a current standard of care (Lomustine), with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine.


Lead Product(s): Berubicin Hydrochloride

Therapeutic Area: Oncology Product Name: RTA 744

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: CNS Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The collaboration will build upon the HLA-G platform pioneered by Invectys to advance novel CAR T cell therapies including lead asset IVS-3001, through preclinical development with CTMC into early-phase clinical studies at MD Anderson.


Lead Product(s): HLA-G/CAR-T Cell Therapy

Therapeutic Area: Oncology Product Name: IVS-3001

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Invectys

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

A single combination treatment with Dermacyte Liquid and Dermacyte Matrix (Human Amniotic Fluid) healed smaller of two wounds in four weeks. Dermacyte Liquid was injected under skin around wounds on patient’s thigh and lower leg.


Lead Product(s): Human Amniotic Fluid

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dermacyte Liquid

Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

Recipient: Merakris Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

To define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of T-Cell Receptor T cells (herein referred to as TCR-T cell drug product administered without IL-2 (Arm A) or with IL-2 (Arm B).


Lead Product(s): TCR-T Cell Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

Recipient: Alaunos Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY